Miguel Abboud to Biomarkers
This is a "connection" page, showing publications Miguel Abboud has written about Biomarkers.
Connection Strength
0.093
-
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11?years. Pediatr Blood Cancer. 2022 08; 69(8):e29716.
Score: 0.033
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
Score: 0.027
-
Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol. 2007 Jan; 136(2):343-4.
Score: 0.011
-
Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease. J Pediatr Hematol Oncol. 2006 Mar; 28(3):147-53.
Score: 0.011
-
Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome. Hemoglobin. 2006; 30(2):165-70.
Score: 0.011